about
Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy.Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review.Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis.Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis.Complications of cirrhosis. I. Portal hypertension.Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD.Assessment of portal hypertension in humans.Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study.Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension.Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.Budd-Chiari syndrome: a review by an expert panel.Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis.Transjugular Intrahepatic Portosystemic Shunt for Acute Variceal Bleeding: A Meta-analysis.CO(2) wedged hepatic venography in the evaluation of portal hypertension.NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats.Metabolomics as a diagnostic tool for idiopathic non-cirrhotic portal hypertension.Endotipsitis: an emerging prosthetic-related infection in patients with portal hypertension.Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis.Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension.Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapyMeasurement of portal pressure and its role in the management of chronic liver disease.Potential role of antioxidants in the treatment of portal hypertension.Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.Primary prophylaxis of esophageal variceal bleeding in cirrhosis.Extrahepatic portal vein thrombosis.Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats.Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis.The clinical use of HVPG measurements in chronic liver disease.A histologic scoring system for prognosis of patients with alcoholic hepatitisHepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.Idiopathic noncirrhotic portal hypertension.Variceal and other portal hypertension related bleeding.Imaging in clinical decision-making for portal vein thrombosis.Nontumoral portal vein thrombosis in patients awaiting liver transplantation.Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension.Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study.Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis.Acute variceal bleeding: risk stratification and management (including TIPS).
P50
Q31034988-3D93C452-9E54-495E-9BC0-52A5DF7CA47DQ33263463-E2D721B0-E138-4848-8875-246C71C1BCB9Q33378073-56A71A90-BFFD-473F-8D80-64A06697A29BQ33383677-B667FBB9-0A02-4DF0-84A8-EB854EB5EBD1Q33870258-F9434188-44F7-4CF7-8D28-1FBA000FAA88Q34234946-3C6B4B77-84D2-41FA-B121-FA03FFDC614DQ34374889-13675F0B-D159-4CDC-B203-5B3DECF0127DQ34469981-37F1A116-EFB7-4675-BFC0-20AAE1A98C8DQ34544992-D3B1F77B-ADE6-409A-B85B-800456F3D149Q34631908-E86BAECF-7A44-40B7-86B4-CE517F2F0F1EQ34735059-D236F546-E635-487D-9EC7-90F3C3C01490Q35066120-79E98369-ECEA-4A6F-9408-906D573577B2Q35131876-1E9C3AB6-3EB5-4A47-8042-BBFB4361FC2FQ35225693-DD044C9B-707C-4989-9175-55038593E71CQ35557611-A5471306-F583-4D0D-82E6-39F1A08980ADQ35761411-619AAAFB-D26C-4A08-8B32-C2A0A91A54CEQ35783812-9E18B958-D8A9-4B94-9510-B5CE8B566D05Q35796456-9745FF68-15EF-4137-8871-7B1AD7AFD723Q35995445-C24F7AC2-4E11-4E60-8236-F2B731025BE6Q36066761-59EC5114-0BFD-43C0-B8F1-E64B7325F27BQ36611305-0463639E-9F92-44C7-86E5-A382991CD543Q36628287-116D86E9-6566-438B-A766-B055F29EB448Q36679952-EA777FA4-92F5-475D-AA63-FEA9D367F780Q36903148-E7CF5A2A-D67C-4826-BA22-42AB2926F090Q37154474-10C1EA9A-8CA2-417C-8DA0-D7632F877E85Q37278281-BD8DE740-CB9F-46BF-A34F-B6F2A4C515C6Q37296246-956CCE21-C8C8-4EBB-97C7-F0409E4C23F6Q37424578-6D0121E9-03BD-4CA1-8D76-32D7901E8C55Q37590666-4ED2FBE0-38B4-4BB7-A1C2-9A724C2C3A14Q37710980-6A2D1980-D725-4FF3-9C8D-74F252FC197BQ37766339-A5539689-30D2-4199-BF23-5E321E958632Q37875824-BDD2A681-2162-49F2-9AF7-BDA1A0FA265BQ38155632-AF65F3D7-F1C4-43B6-A448-0AA1D93A971AQ38178081-A8D58F33-1FFC-47F7-8BBB-BD594475D712Q38673769-30BE8B87-61F0-48B7-A042-0854479FAD94Q38764257-771C08AB-1F84-4397-B48A-4E1B495C3C08Q38994735-7A82299A-F39E-475B-BFDA-AEBCB93446B2Q39082512-FAEACE8C-4E45-456F-ABD8-397DC268CAD8Q39251865-CA620898-38F2-4117-BB37-ADAAC53B039FQ39387277-3A1FC8BD-7824-4071-A36D-E77EC1557D1D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Juan Carlos García-Pagan
@ast
Juan Carlos García-Pagan
@en
Juan Carlos García-Pagan
@es
Juan Carlos García-Pagan
@nl
Juan Carlos García-Pagan
@sl
type
label
Juan Carlos García-Pagan
@ast
Juan Carlos García-Pagan
@en
Juan Carlos García-Pagan
@es
Juan Carlos García-Pagan
@nl
Juan Carlos García-Pagan
@sl
prefLabel
Juan Carlos García-Pagan
@ast
Juan Carlos García-Pagan
@en
Juan Carlos García-Pagan
@es
Juan Carlos García-Pagan
@nl
Juan Carlos García-Pagan
@sl
P1053
P-6291-2015
P106
P21
P31
P3829
P496
0000-0001-9032-4954